Endologix Added to Russell Indexes

IRVINE, Calif., June 30 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq:
ELGX), developer of minimally invasive treatments for aortic disorders, today
announced that it has been added to the Russell 3000(R), Russell 2000(R) and
Russell Global Indexes, effective June 26, 2009 after the close of the U.S.
markets.

John McDermott, President and CEO, said, "We are pleased that Endologix is now
included in the Russell Indexes, which has $4 trillion in assets currently
benchmarked to them. The addition should increase the Company's exposure to
potential institutional and retail investors as we continue to roll out our
new products and increase our share of the abdominal aortic aneurysm market."

The annual reconstitution of Russell's U.S. indexes captures the 4,000 largest
U.S. stocks as of the end of May, ranking them by total market capitalization.
Membership in the Russell 3000, which remains in place for one year, means
automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell
2000 Index as well as the appropriate growth and value style indexes. Russell
determines membership for its equity indexes primarily by objective,
market-capitalization rankings and style attributes. The Russell 3000 also
serves as the U.S. component to the Russell Global Index, which Russell
launched in 2007.

Russell indexes are widely used by investment managers and institutional
investors for index funds and as benchmarks for both passive and active
investment strategies. An industry-leading $4 trillion in assets currently are
benchmarked to them.

About Endologix

Endologix, Inc. develops and manufactures minimally invasive treatments for
aortic disorders. The Company's flagship product is the Powerlink(R) System,
which is an endovascular stent graft for the treatment of abdominal aortic
aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest
artery in the body, resulting in a balloon-like enlargement. Once AAA
develops, it continues to enlarge and, if left untreated, becomes increasingly
susceptible to rupture. The overall patient mortality rate for ruptured AAA is
approximately 75%, making it a leading cause of death in the U.S. Additional
information can be found on Endologix's Web site at www.endologix.com.

Except for historical information contained herein, this news release contains
forward-looking statements with respect to the Company's exposure to potential
institutional and retail investors the accuracy of which are necessarily
subject to risks and uncertainties, all of which are difficult or impossible
to predict accurately and many of which are beyond the control of Endologix.
The Company undertakes no obligation to update its forward looking statements.
Please refer to the Company's Annual Report on Form 10-K for the year ended
December 31, 2008, and the Company's other filings with the Securities and
Exchange Commission, for more detailed information regarding factors that may
cause actual results to differ materially from those expressed or implied.

COMPANY CONTACT: INVESTOR CONTACTS:
Endologix, Inc. The Ruth Group
John McDermott, CEO Nick Laudico (646) 536-7030
(949) 595-7200 Zack Kubow (646) 536-7020
www.endologix.com

SOURCE Endologix, Inc.

John McDermott, CEO of Endologix, Inc., +1-949-595-7200; or INVESTOR, Nick
Laudico, +1-646-536-7030, or Zack Kubow, +1-646-536-7020, both of The Ruth
Group